% alzhub.org library filter
% Source: https://alzhub.org/research?author=Sperling+R&score_min=67
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{salloway2014-24450891,
  author  = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}},
  journal = {The New England journal of medicine},
  year    = {2014},
  doi     = {10.1056/nejmoa1304839},
  pmid    = {24450891},
  url     = {https://doi.org/10.1056/nejmoa1304839}
}

@article{salloway2009-19923550,
  author  = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others},
  title   = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2009},
  doi     = {10.1212/wnl.0b013e3181c67808},
  pmid    = {19923550},
  url     = {https://doi.org/10.1212/wnl.0b013e3181c67808}
}

@article{sperling2021-33464300,
  author  = {Sperling, R. and Henley, D. and Aisen, P. S. and Raman, R. and Donohue, M. C. and Ernstrom, K. and Rafii, M. S. and Streffer, J. and others},
  title   = {{Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2020.4857},
  pmid    = {33464300},
  url     = {https://doi.org/10.1001/jamaneurol.2020.4857}
}

@article{salloway2018-29914022,
  author  = {Salloway, S. P. and Sperling, R. and Fox, N. C. and Sabbagh, M. N. and Honig, L. S. and Porsteinsson, A. P. and Rofael, H. and Ketter, N. and others},
  title   = {{Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2018},
  doi     = {10.3233/jad-171157},
  pmid    = {29914022},
  url     = {https://doi.org/10.3233/jad-171157}
}

@article{salloway2011-21917766,
  author  = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others},
  title   = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}},
  journal = {Neurology},
  year    = {2011},
  doi     = {10.1212/wnl.0b013e3182309fa5},
  pmid    = {21917766},
  url     = {https://doi.org/10.1212/wnl.0b013e3182309fa5}
}

@article{liu2018-29429971,
  author  = {Liu, E. and Wang, D. and Sperling, R. and Salloway, S. and Fox, N. C. and Blennow, K. and Scheltens, P. and Schmidt, M. E. and others},
  title   = {{Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000005060},
  pmid    = {29429971},
  url     = {https://doi.org/10.1212/wnl.0000000000005060}
}